Document is current
Any future updates will be listed below
-
Authors
Liu, Jia https://orcid.org/0000-0003-4442-6516
Yang, Jianwei
Sun, Yuping
Gong, Jifang https://orcid.org/0000-0003-3798-7024
Yue, Jinbo
Pan, Yueyin
Sun, Meili https://orcid.org/0000-0002-4914-6508
Song, Rongfeng
Xiao, Xiuying
Tazbirkova, Andrea
Ruan, Jian
Liu, Zhenyang
Liu, Zimin
Li, Zhihua
Sheng, Lili
Qin, Yanru
Ying, Jieer
Yu, Xianjun https://orcid.org/0000-0002-6697-7143
Zhang, Jian
Mou, Yiping
Lu, Chuangxin
Chen, Ping
Li, Suyi
Li, Jie
Qu, Xiujuan
Deng, Ting
Du, Juan
Zhou, Aiping
Li, Enxiao
Yuan, Xianglin
Liang, Xinjun
Yu, Weiming
Morris, Michelle https://orcid.org/0000-0002-0246-0786
Luo, Yang
Zhao, Xin
Guo, Yingmei
Zhou, Hui
Shen, Lin https://orcid.org/0000-0002-8798-4756
- License Information
-
More Information
Article History
Received: 10 December 2024
Accepted: 19 May 2025
First Online: 16 July 2025
Competing interests
: J.L. declares honoraria from Merck Sharp & Dohme and Specialised Therapeutics, consulting or advisory roles for Starpharma and Greywolf Therapeutics, research funding from Starpharma, ViroCure, Corvus Pharmaceuticals, Relay Therapeutics, ALX Oncology, IDEAYA Biosciences, Innovent Biologics, Greywolf Therapeutics, Merck Sharp & Dohme, Regeneron, Bristol Myers Squibb, AbbVie and AVEO, and travel, accommodation and expenses from Starpharma, ImmVirX, Merck Sharp & Dohme and Innovent Biologics. Y.L., X.Z., Y.G. and H.Z. are employees of Innovent Biologics. The other authors declare no competing interests.
